bioMerieux (FR:BIM) has released an update.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
bioMerieux, a global leader in in vitro diagnostics, has announced the CE-marking of their new VIDAS VITAMIN B12 TOTAL test, which measures vitamin B12 levels in human serum or plasma. This automated quantitative test, which is essential for diagnosing potential B12 deficiencies, will be available on all VIDAS immunoassay systems. The launch aims to enhance the comprehensive VIDAS test portfolio and is set to begin in select countries at the end of 2024, with a wider release in early 2025.
For further insights into FR:BIM stock, check out TipRanks’ Stock Analysis page.